. Author manuscript; available in PMC: 2011 Jan 1.

Published in final edited form as: Med Decis Making. 2009 Jul 27;30(1):45–57. doi: 10.1177/0272989X09341588

Table 3.

Associations^* between subject characteristics and preference for HCV treatment associated with severe and mid side effects.

Characteristic	Preference for treatment associated with severe side effects	Preference for treatment associated with mild side effects
Degree of fibrosis	4.6 (2.1 – 10.0)	2.8 (1.3 – 6.1)
Gender	5.3 (1.3 – 21.1)	5.3 (1.0 – 28.1)
Genotype	2.9 (0.8 – 10.3)	2.1 (0.5 – 8.0)
HCV-related quality of life	1.01 ( 0.99 – 1.03)	1.02 ( 1.00 – 1.04)
Expectation of developing cirrhosis	1.01 (1.00 – 1.03)	1.01 (0.99 – 1.03)
Decisional conflict	0.97 (0.94 – 0.99)	0.97 (0.95 – 0.99)
Trust	1.03 (0.97 – 1.08)	1.05 (0.99 – 1.11)

Wald 95% confidence interval for adjusted odds ratios